Prevalence and Characteristics of Chronic Pain in Buprenorphine and Methadone-Maintained Patients.
buprenorphine
chronic pain
epidemiology
methadone
opioid agonist treatment
pain management
prevalence
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2021
2021
Historique:
received:
14
12
2020
accepted:
29
03
2021
entrez:
13
5
2021
pubmed:
14
5
2021
medline:
14
5
2021
Statut:
epublish
Résumé
Chronic pain and substance use disorders frequently co-occur. Indeed, chronic pain is highly prevalent, affecting 23-68% of patients receiving opioid agonist treatments (OAT) worldwide. The majority of available estimates come from American studies, but data are still lacking in Europe. We aim to provide European estimates of the prevalence of chronic pain in patients receiving OAT using French data, since France is the first European country in terms of number of patients with OAT. The secondary objectives were to characterize the features and management of chronic pain, as well identify associated risk factors. We conducted a multicenter, cross-sectional study, recruiting patients treated either with buprenorphine or methadone in 19 French addiction centers, from May to July 2016. All participants had to complete a semi-directed questionnaire that collected sociodemographic and medical data, pain characteristics, and licit or illicit drug consumption. In total, 509 patients were included. The prevalence of chronic pain was estimated at 33.2% (95% CI: 29.1-37.3). Compared to non-chronic pain patients, chronic pain patients were older (38.4 vs. 36.1 years,
Identifiants
pubmed: 33981257
doi: 10.3389/fpsyt.2021.641430
pmc: PMC8107279
doi:
Types de publication
Journal Article
Langues
eng
Pagination
641430Informations de copyright
Copyright © 2021 Delorme, Pennel, Brousse, Daulouède, Delile, Lack, Gérard, Dematteis, Kabore, Authier, Chenaf and TOXIDOL Study group.
Déclaration de conflit d'intérêts
GB received sponsorship to attend scientific meetings, speaker honoraria, from Lundbeck, Merck-Lipha, Indivior, Bristol-Myers Squibb, Otsuka, Eutherapie, Sanofi Aventis, and AstraZeneca. MD received honoraria for speaking at conferences from Indivior, Recordati, and Camurus Laboratories, and honoraria for consultancy from Indivior, Camurus, and Accord Healthcare. LP received speaker honoraria from Recordati and Indivior laboratories. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Gen Intern Med. 2009 Apr;24(4):482-8
pubmed: 19189194
Pain. 2017 Nov;158(11):2092-2107
pubmed: 28767506
J Addict Med. 2008 Jun;2(2):108-11
pubmed: 21768980
Pain Manag Nurs. 2006 Mar;7(1):31-41
pubmed: 16490734
Am J Addict. 2013 May-Jun;22(3):212-7
pubmed: 23617861
Assessment. 2000 Jun;7(2):103-11
pubmed: 10868247
Drug Alcohol Depend. 2015 Dec 1;157:143-9
pubmed: 26518253
J Clin Psychiatry. 2009 Sep;70(9):1213-8
pubmed: 19607760
Drug Alcohol Rev. 2013 Sep;32(5):489-94
pubmed: 23594352
Expert Opin Pharmacother. 2019 Nov;20(16):1993-2005
pubmed: 31418602
J Pain. 2011 Jan;12(1):41-50
pubmed: 20561825
JAMA. 2003 May 14;289(18):2370-8
pubmed: 12746360
Pain Med. 2014 Dec;15(12):2075-86
pubmed: 25041442
Fundam Clin Pharmacol. 2013 Dec;27(6):672-82
pubmed: 23510229
J Pain Symptom Manage. 2000 Oct;20(4):237-45
pubmed: 11027904
Front Psychiatry. 2018 Jul 23;9:335
pubmed: 30083113
J Pain Symptom Manage. 2000 Jan;19(1):53-62
pubmed: 10687327
Subst Abus. 2012;33(2):103-13
pubmed: 22489582
J Clin Psychiatry. 2016 Oct;77(10):1413-1419
pubmed: 27574837
J Pain. 2009 Mar;10(3):316-22
pubmed: 19101210
Drug Alcohol Depend. 2004 Jan 7;73(1):23-31
pubmed: 14687956
J Pain Palliat Care Pharmacother. 2002;16(1):105-9
pubmed: 14650454
Ann Acad Med Singap. 1994 Mar;23(2):129-38
pubmed: 8080219
Pain. 2021 Jan;162(1):195-202
pubmed: 32701648
Pain Med. 2014 Sep;15(9):1540-8
pubmed: 24703517
J Pharm Pharm Sci. 2016;19(1):127-36
pubmed: 27096697
Subst Abus. 2016 Jul-Sep;37(3):387-391
pubmed: 26731299
Schizophr Bull. 1998;24(4):589-608
pubmed: 9853791
Subst Abuse. 2015 Sep 10;9:59-80
pubmed: 26417202
J Gen Intern Med. 2015 Jul;30(7):935-41
pubmed: 25678375
J Addict Med. 2010 Jun;4(2):81-7
pubmed: 21769025
Pain. 2001 Feb 1;90(1-2):91-6
pubmed: 11166974
J Clin Psychiatry. 2006;67 Suppl 7:5-9
pubmed: 16961418
Pain Physician. 2013 Nov-Dec;16(6):E739-47
pubmed: 24284855
Am J Addict. 2009 Mar-Apr;18(2):117-21
pubmed: 19283562
J Pain. 2015 Sep;16(9):887-94
pubmed: 26101814
Pain. 2005 Feb;113(3):340-346
pubmed: 15661442
Pain Med. 2017 Nov 1;18(11):2152-2161
pubmed: 28177509
Drug Alcohol Depend. 2013 Feb 1;128(1-2):161-5
pubmed: 22951068
J Gen Intern Med. 2002 May;17(5):327-33
pubmed: 12047728
Drug Alcohol Depend. 2016 Sep 01;166:26-31
pubmed: 27422763